Happy New Year!

Announcements

- Expanded Scope - Same Vision
- New Translational Research Deputy Directors
- Programmatic Investment Grant Winners
- Translational Allies - T*allies - How we can help you

Expanded Scope - Same Vision

We are excited to announce the expansion of STTR programming, as Dr. Ollie Press has championed the inclusion of liquid tumor entities within STTR. With the approval of Dr. Gary Gilliland, Dr. Paul Ramsey, and Dr. Fred Appelbaum, Dr. Eric Holland and Desert Horse-Grant will now focus on translational “cancer” research under one umbrella. Please contact desert@fredhutch.org with any questions.

In 2016, we welcome four new liquid and one additional solid tumor group into STTR: leukemia, lymphoma, myeloma, myelodysplastic syndromes/myeloproliferative neoplasms, and anogenital cancers. As a result of the widening scope, we will change our name in the coming year.

New Translational Research Deputy Directors

We have formally invited one translational research leader per tumor type as Deputy Director of STTR, to help lead our community in translational research. We look forward to partnering with Clinical Research Program Directors and others to achieve overarching research goals. We are excited to announce one-year appointments for the first STTR Deputy Directors. To view leader bios online, click their name.

Anogenital Cancer - Dr. Denise Galloway

Dr. Galloway studies the mechanisms by which human papillomaviruses contribute to cancer, with an emphasis on types most likely to progress to cervical cancer. They work to understand the natural history of genital HPV infections and why only a small subset of women infected with high-risk HPVs develop cancer.
Bladder Cancer - Dr. R. Bruce Montgomery
Dr. Montgomery is clinical director of genitourinary medical oncology, carrying out research and seeing men and women with genitourinary cancers at SCCA/UWMC. He specialized in the treatment of high risk and advanced prostate cancer, treatment of bladder and testicular cancer, and drug resistance to hormonal therapy and taxane chemotherapy.

Brain Cancer - Dr. Eric Holland
Dr. Holland is a neurosurgeon and brain cancer researcher. His research goal is to address the molecular basis of brain tumors and develop new treatment approaches. His research focuses on developing mouse models of brain cancer that mimic how the disease behaves in patients.

Breast Cancer - Dr. Peggy Porter
Dr. Porter and her lab focus on identifying and understanding the molecular events in normal and cancer cells that are associated with the initiation and progression of human cancer, with a focus on breast and anogenital cancers. They also investigate the molecular profiles that distinguish different types of cancer or determine an individual’s cancer risk.

Colorectal Cancer - Dr. William Grady
Dr. Grady’s clinical focus is on the management of gastrointestinal cancer familial syndromes, colon cancer prevention, and Barrett’s Esophagus. His research focuses on the molecular and cell biology of gastrointestinal cancer, genetic and epigenetic alterations in cancer, cancer biomarkers and hereditary cancer syndromes.

Head & Neck Cancer - Dr. Eduardo Mendez
Dr. Mendez specializes in the surgical treatment of head and neck cancer, including reconstruction of head and neck cancer defects. He uses minimally-invasive approaches which include robotic-assisted surgery and transoral laser microsurgery. His research focuses on markers of disease progression in head and neck cancer and in developing novel targeted therapies against these tumors.

Leukemia – Dr. Jerry Radich
Dr. Radich is a medical oncologist who specializes in molecular genetics of leukemia. Dr. Radich studies why patients respond or relapse after therapy, and his lab also develops methods to detect minimal residual disease, as well as devising methods that can be used in the developing world.
Lung Cancer - Dr. A. McGarry Houghton
Dr. Houghton is a pulmonologist specializing in the early detection of lung cancer. His group is investigating the role of innate immune cells within the tumor microenvironment, beginning with how they have been recruited, and followed by understanding the mechanism by which a specific immune cell effector has impacted lung tumor growth.

Lymphoma – Dr. Ollie Press
Dr. Press is a medical oncologist with a primary interest in developing novel immunotherapies for treatment of hematologic malignancies using monoclonal antibodies, immunotoxins, radioimmunoconjugates, antibody-drug conjugates, adoptive T cell therapy, and antibody-targeted therapy with nanoparticles and siRNA. His research involves genetic engineering of antibody derivatives as well as experiments with cell lines, mouse tumor models, and human clinical trials of novel agents for lymphomas, leukemias, and multiple myeloma.

MDS/MPN – Dr. Joachim Deeg
Dr. Deeg treats bone marrow failure such as aplastic anemia and blood cancers, such as myelodysplastic syndrome, leukemia, and myelofibrosis. His research interests are in pathophysiology, genetics and epigenetics of MDS [role of transcription factors in regulation], inflammatory responses and GVHD, separation of GVHD and GVL effects by AAT, and iron and allogeneic responses.

Myeloma – Dr. Damian Green
Dr. Green is a translational oncologist and stem cell transplant specialist who cares for patients with blood disorders. His clinical expertise is in multiple myeloma, lymphoma, amyloidosis, stem cell transplantation, and radioimmunotherapy. Dr. Green’s laboratory and his clinical research program are focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.

Ovarian Cancer – Dr. Nicole Urban
Dr. Urban’s research focuses on methods designed to improve the performance, efficacy, and cost-effectiveness of breast and ovarian cancer screening tools, with particular emphasis on the discovery, development, and validation of markers for use in cancer risk assessment and screening.

Pancreas Cancer – Dr. Sunil Hingorani
Dr. Hingorani is a medical oncologist and cancer biologist specializing in pancreas cancer. He runs a translational research program dedicated to developing new early detection and treatment strategies. His laboratory studies the molecular and cellular pathogenesis of pancreas cancer primarily through the use of genetically engineered mouse models.
**Prostate Cancer - Dr. Peter Nelson**

Dr. Nelson is an oncologist specializing in therapies for early- and late-stage prostate cancer. The focus of current work involves defining the molecular determinants driving prostate cancer development, metastatic spread, and treatment resistance. The research studies are designed to identify new therapeutics and create prognostic and predictive tools that translate into effective strategies capable of preventing and curing prostate cancer.

**Sarcoma - Dr. Seth Pollack**

Dr. Pollack is an expert on sarcomas, cancers of the bone and soft tissues. The SCCA is consistently one of the highest enrolling sites for national sarcoma clinical trials, including trials focused on patients with especially rare sarcoma subtypes. As the focus of his research, Dr. Pollack is developing new ways to enhance a sarcoma patient’s immune response against their cancer, and to thereby improve patient outcomes.

*We hope you will join us in congratulating the new Deputy Directors!*
STTR Translational Allies - T*allies - How we can help you

We have three T*allies responsible for support and coordination across our cancer programs. Please contact your T*allie if you would like to learn more or get help with any of the following:

- **Grant support**: 3-year Granting Road Map; support for multi-PI grant applications; STTR peer-reviewed granting program

- **Collaboration**: Translational Research Meetings; 1-on-1 meetings; identifying faculty collaborators; access to the STTR Member site; portfolio and metrics evaluations; retreat; special requests

- **Facilitation with Support Services**: connect to Development, Communications, IT [Casis, HIDRA, Argos]; Fred Hutch, UW Medicine, SCCA joint initiatives; database and/or biorepository standardization; social media

Rachel Galbraith  
(206) 667-5183

Jalle Gebisa  
(206) 667-4748

Nola Klemfuss  
(206) 667-3042

Brain  
Anogenital  
Head & Neck  
Lung  
Sarcoma

Breast  
Ovary  
Colorectal  
Pancreas  
STTR Granting Program

Prostate  
Bladder  
Leukemia  
Lymphoma  
Myeloma  
MDS/MPN